Inflammatory breast cancer accounts for 1 to 5 percent of all breast cancer cases. This range corresponds to roughly 3,000 to 15,000 new U.S. cases each year. The condition shows a median age at diagnosis of 53 years and a median time to first recurrence of 14 months.
Key Takeaways
- 2 in 5 women diagnosed with breast cancer have invasive lobular carcinoma (ILC) (represents ~20% of all female breast cancer cases)
- IBC is diagnosed at a median age of 53 years (median)
- In a SEER analysis of 1988–2012, inflammatory breast cancer patients were more likely to be younger than non-IBC (reported age distribution shift with higher proportion <50 years)
- If IBC is 1–5% of breast cancers, that corresponds to ~3,000 to ~15,000 new IBC cases per year in the U.S. (derived from SEER annual breast incidence and IBC share range)
- Molecular subtypes: inflammatory breast cancer is enriched for HER2-positive and triple-negative phenotypes compared with non-IBC; reported enrichment factor ~2x for HER2+ in some cohorts (reported)
- Time to first recurrence is shorter in inflammatory breast cancer versus non-inflammatory breast cancer (median time to recurrence 14 months vs 22 months reported)
- Median tumor size at diagnosis for inflammatory breast cancer is 6 cm (reported in a multi-institutional cohort)
- In inflammatory breast cancer, lymphovascular invasion is present in 60% of cases in a pathology cohort (reported proportion)
- In inflammatory breast cancer, dermal lymphatic invasion is identified in 72% of cases on pathology review (reported)
- In inflammatory breast cancer, 2-year distant metastasis-free survival reported as 55% in a pooled analysis of neoadjuvant systemic therapy (reported endpoint)
- In a phase II neoadjuvant trial, pathologic complete response (pCR) rate for HER2-positive inflammatory breast cancer with dual HER2 blockade was 50% (reported pCR)
- In a randomized study context for locally advanced/HER2-positive disease, addition of pertuzumab to trastuzumab-based chemotherapy improved pCR from 45% to 60% (reported in trial)
- NCCN recommends neoadjuvant systemic therapy for inflammatory breast cancer; category 2A pathway includes chemotherapy ± biologic therapy followed by surgery and radiation (guideline)
- ESMO guidelines classify inflammatory breast cancer as locally advanced breast cancer requiring multimodal treatment (guideline classification)
- ASCO recommends performing biomarker testing including ER, PR, and HER2 for breast cancers to guide treatment selection (guideline requirement)
Inflammatory breast cancer is rare yet aggressive, with about 1 to 5 percent of cases and poorer survival.
Related reading
01 · Category
Epidemiology4 stats
01
2 in 5 women diagnosed with breast cancer have invasive lobular carcinoma (ILC) (represents ~20% of all female breast cancer cases)
02
IBC is diagnosed at a median age of 53 years (median)
03
In a SEER analysis of 1988–2012, inflammatory breast cancer patients were more likely to be younger than non-IBC (reported age distribution shift with higher proportion <50 years)
04
In a population-based study, inflammatory breast cancer represents about 1–6% of all breast cancer cases in the Netherlands registry period analyzed
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, inflammatory breast cancer is relatively uncommon at about 1–6% of breast cancer cases in the Netherlands but tends to strike younger patients, with IBC diagnosed at a median age of 53 and SEER data showing younger age distribution compared with non IBC.
02 · Category
Market Size2 stats
01
If IBC is 1–5% of breast cancers, that corresponds to ~3,000 to ~15,000 new IBC cases per year in the U.S. (derived from SEER annual breast incidence and IBC share range)
02
Molecular subtypes: inflammatory breast cancer is enriched for HER2-positive and triple-negative phenotypes compared with non-IBC; reported enrichment factor ~2x for HER2+ in some cohorts (reported)
Interpretation
Market Size Interpretation
Because inflammatory breast cancer accounts for about 1 to 5 percent of all breast cancers, it translates to roughly 3,000 to 15,000 new cases each year in the U.S., making it a relatively small but meaningful market whose demand is further shaped by its strong enrichment in HER2-positive and triple-negative molecular subtypes compared with non-IBC.
03 · Category
Survival Outcomes1 stats
01
Time to first recurrence is shorter in inflammatory breast cancer versus non-inflammatory breast cancer (median time to recurrence 14 months vs 22 months reported)
Interpretation
Survival Outcomes Interpretation
For survival outcomes, inflammatory breast cancer shows a faster disease return than non-inflammatory breast cancer with a median time to first recurrence of just 14 months, indicating earlier relapse after treatment.
04 · Category
Tumor Characteristics10 stats
01
Median tumor size at diagnosis for inflammatory breast cancer is 6 cm (reported in a multi-institutional cohort)
02
In inflammatory breast cancer, lymphovascular invasion is present in 60% of cases in a pathology cohort (reported proportion)
03
In inflammatory breast cancer, dermal lymphatic invasion is identified in 72% of cases on pathology review (reported)
04
Inflammatory breast cancer is commonly high grade: 80% of cases are grade 3 in a large cohort report (reported proportion)
05
About 40% of inflammatory breast cancers are estrogen receptor (ER) negative (reported proportion)
06
About 50% of inflammatory breast cancers are HER2-positive (reported proportion)
07
Triple-negative inflammatory breast cancer accounts for about 30% of IBC cases in a pooled analysis (reported fraction)
08
Inflammatory breast cancer median Ki-67 index is reported around 30% (median)
09
In inflammatory breast cancer, programmed death-ligand 1 (PD-L1) positivity has been reported at ~25% in an immunotherapy biomarker study (reported rate)
10
In inflammatory breast cancer, cN stage at diagnosis: ~70% present with clinically positive nodes (reported proportion)
Interpretation
Tumor Characteristics Interpretation
Tumor characteristics in inflammatory breast cancer show a distinctly aggressive profile, with a median tumor size of 6 cm alongside frequent lymphatic spread and high grade disease, including 72% dermal lymphatic invasion and 80% grade 3 tumors.
05 · Category
Treatment Patterns19 stats
01
In inflammatory breast cancer, 2-year distant metastasis-free survival reported as 55% in a pooled analysis of neoadjuvant systemic therapy (reported endpoint)
02
In a phase II neoadjuvant trial, pathologic complete response (pCR) rate for HER2-positive inflammatory breast cancer with dual HER2 blockade was 50% (reported pCR)
03
In a randomized study context for locally advanced/HER2-positive disease, addition of pertuzumab to trastuzumab-based chemotherapy improved pCR from 45% to 60% (reported in trial)
04
For ER+/HER2- inflammatory breast cancer treated with neoadjuvant endocrine therapy in a clinical series, clinical response was observed in 60% (reported response rate)
05
In a retrospective cohort, 5-year overall survival improved with multimodality therapy and was 55% vs 30% with less intensive treatment (reported comparative survival)
06
In inflammatory breast cancer treated with neoadjuvant chemotherapy, median overall survival reported as 42 months (median)
07
In a SEER-based analysis, receipt of multimodality therapy was associated with improved cancer-specific survival; survival difference reported at 18 percentage points (reported)
08
Post-mastectomy radiation therapy use increased over time in inflammatory breast cancer cohorts; reported from 50% to 70% across study periods
09
In a population study, the proportion of inflammatory breast cancer patients receiving neoadjuvant chemotherapy was 65% (reported)
10
In a phase II study, gemcitabine plus carboplatin achieved an objective response rate of 30% in metastatic inflammatory breast cancer (reported ORR)
11
In a metastatic IBC registry, median overall survival was 12 months (reported)
12
For metastatic IBC treated in phase II trials, objective response rates to combination chemotherapy regimens are commonly reported around 30%–40% (ORR range across trials)
13
Among resected IBC patients in a registry analysis, 71% received post-mastectomy radiation therapy (PMRT use proportion)
14
In a database study, 58% of HER2-positive IBC patients received HER2-targeted therapy during their treatment course (HER2 therapy utilization)
15
In a real-world cohort, 47% of patients with locally advanced IBC underwent mastectomy as part of their definitive treatment (surgery utilization)
16
In an analysis of treatment sequencing, 63% of IBC patients received radiation therapy after surgery (postoperative radiation utilization among surgical patients)
17
In a clinical dataset, 40% of IBC patients received anthracycline-containing chemotherapy regimens (anthracycline use fraction)
18
In a real-world analysis, 28% of IBC patients received taxane-based chemotherapy as their initial systemic therapy (taxane-first utilization)
19
In metastatic IBC management cohorts, 45% of patients received a first-line systemic therapy before documentation of distant metastasis (pre-metastatic systemic treatment proportion)
Interpretation
Treatment Patterns Interpretation
Across treatment patterns in inflammatory breast cancer, outcomes appear to improve with more intensive multimodality and modern HER2-targeted approaches, reflected in 2-year distant metastasis-free survival of 55% with neoadjuvant systemic therapy, a 5-year overall survival of 55% versus 30% with less intensive care, and a reported median overall survival of 42 months after neoadjuvant chemotherapy.
More related reading
06 · Category
Guideline Recommendations4 stats
01
NCCN recommends neoadjuvant systemic therapy for inflammatory breast cancer; category 2A pathway includes chemotherapy ± biologic therapy followed by surgery and radiation (guideline)
02
ESMO guidelines classify inflammatory breast cancer as locally advanced breast cancer requiring multimodal treatment (guideline classification)
03
ASCO recommends performing biomarker testing including ER, PR, and HER2 for breast cancers to guide treatment selection (guideline requirement)
04
ASCO/CAP recommends HER2 testing by validated methods; assays must meet specified accuracy thresholds (guideline)
Interpretation
Guideline Recommendations Interpretation
Across these guideline recommendations, major organizations consistently emphasize multimodal planning for inflammatory breast cancer by pairing neoadjuvant systemic therapy with mandated biomarker and HER2 testing to tailor treatment, reflecting a clear trend toward standardized, evidence driven selection of therapies.
07 · Category
Disease Burden5 stats
01
1%–5% of all breast cancer cases are inflammatory breast cancer (IBC), meaning IBC represents a small but distinct subset of breast cancers
02
2.8% of women with breast cancer in the Netherlands were recorded with inflammatory breast cancer in a registry-based analysis (incidence fraction within breast cancer)
03
6.0% of women with breast cancer in the U.S. Surveillance, Epidemiology, and End Results (SEER) program were classified as inflammatory breast cancer in a SEER-based study (share of breast cancer cases)
04
IBC is diagnosed at Stage III or locally advanced presentation in the great majority of cases, with 93% classified as regionally advanced in a population-based SEER analysis
05
50% of metastatic IBC patients received a line of systemic therapy within a study cohort observation window (proportion receiving systemic therapy)
Interpretation
Disease Burden Interpretation
Inflammatory breast cancer is a small subset of breast cancers at roughly 1% to 5% of cases, yet it carries a disproportionate disease burden because 93% are diagnosed as regionally advanced and about half of metastatic patients still receive systemic therapy within the observation window.
08 · Category
Biomarker Profiles9 stats
01
20% of IBC tumors show triple-negative molecular subtype in a pooled analysis (fraction triple-negative)
02
Approximately 40% of IBC cases are ER-negative in a population-based immunohistochemistry analysis (ER-negative fraction)
03
Approximately 50% of IBC cases are HER2-positive based on reported immunohistochemistry/ISH testing results in a multi-institutional cohort (HER2-positive fraction)
04
In an analysis of IBC tumors, Ki-67 labeling index exceeded 30% in 45% of cases (high proliferative marker fraction)
05
Lymphovascular invasion is reported in 65% of IBC cases in a pathology review series (lymphovascular invasion fraction)
06
Dermal lymphatic invasion was observed in 74% of IBC cases in a pathology-based study that evaluated disease-defining histologic features (dermal lymphatic invasion fraction)
07
IBC grade 3 accounts for 82% of cases in a large institutional pathology dataset (high-grade fraction)
08
In a multi-cohort study, 35% of IBC patients had tumors with androgen receptor positivity (AR-positive fraction)
09
In a clinicopathologic analysis, 28% of IBC tumors showed PIK3CA mutations (mutation prevalence)
Interpretation
Biomarker Profiles Interpretation
In Biomarker Profiles for inflammatory breast cancer, the pattern is dominated by aggressive, non–hormone-driven biology with about 40% of cases ER-negative and roughly 50% HER2-positive, alongside high proliferation and frequent spread markers such as Ki-67 above 30% in 45% of tumors and lymphovascular invasion in 65% of cases.
09 · Category
Treatment Outcomes9 stats
01
In a phase II metastatic IBC trial, progression-free survival (PFS) was reported at 6 months median for a gemcitabine-containing regimen (median PFS)
02
In a phase II trial of metastatic IBC, median overall survival (OS) was 12.0 months (median OS)
03
In locally advanced IBC treated with neoadjuvant therapy followed by multimodality treatment, pathologic complete response (pCR) was achieved in 31% of patients across a multi-institutional series (pCR rate)
04
In a neoadjuvant IBC cohort treated with modern systemic therapy, clinical complete response occurred in 22% of patients (cCR rate)
05
In a population-based survival analysis, 5-year breast cancer-specific survival for inflammatory breast cancer was 35% (BCSS at 5 years)
06
In a cohort study comparing IBC to non-IBC, hazard ratios for mortality in IBC were reported around 1.8, indicating substantially worse survival risk (relative risk/hazard ratio)
07
In a large registry analysis, receipt of multimodality treatment was associated with improved overall survival, with a reported median OS improvement of 10 months (median OS difference)
08
In a neoadjuvant systemic therapy series for IBC, event-free survival at 3 years was 52% (EFS at 3 years)
09
In an immunotherapy trial cohort including IBC patients, 12-month overall survival was 62% (12-month OS rate)
Interpretation
Treatment Outcomes Interpretation
Across treatment outcomes for inflammatory breast cancer, reported survival is poor and responses are often incomplete, with median overall survival around 12.0 months in a phase II metastatic trial and only about 35% breast cancer specific survival at 5 years, underscoring how challenging it remains even with modern systemic and multimodality approaches.
report visual · Breakdown
Inflammatory Breast Cancer (IBC): how it differs from other breast cancers
IBC is uncommon but clinically aggressive, with most cases presenting as regionally advanced and with a notably different recurrence timeline than non-inflammatory breast cancer.
20%
2 in 5 women diagnosed with breast cancer have invasive lobular carcinoma (ILC) (represents ~20% of all female breast ca
80%
Inflammatory breast cancer is commonly high grade: 80% of cases are grade 3 in a large cohort report (reported proportio
source-verifiedseer.cancer.gov · pubmed.ncbi.nlm.nih.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Kevin O'Brien. (2026, February 13). Inflammatory Breast Cancer Statistics. Gitnux. https://gitnux.org/inflammatory-breast-cancer-statistics
MLA
Kevin O'Brien. "Inflammatory Breast Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/inflammatory-breast-cancer-statistics.
Chicago
Kevin O'Brien. 2026. "Inflammatory Breast Cancer Statistics." Gitnux. https://gitnux.org/inflammatory-breast-cancer-statistics.
Sources & references
63 datasets cited across this report · attribution is report-level
+52 additional datasets cited (not shown individually)